Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients
Arch. bronconeumol. (Ed. impr.)
; 60(1): 23-32, enero 2024.
Article
in En
| IBECS
| ID: ibc-229518
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Background:
Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission.ObjectivesTo ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission.MethodsA multicenter, real-life study involving severe asthma patients in Spain. Various outcomes were assessed to gauge response and clinical remission against established criteria.ResultsThe study included 429 patients, 209 (48.7%) omalizumab, 112 (26.1%) mepolizumab, 19 (4.4%) reslizumab and 89 (20.7%) benralizumab, with a mean treatment duration of 55.3±38.8 months. In the final year of treatment, 218 (50.8%) were super-responders, 173 (40.3%) responders, 38 (8.9%) non-responders, and clinical remission in 116 (27%), without differences among biologics. The short-term non-responders (<6 months) were 25/545 (4.6%). Substantial variations in response and clinical remission were observed when applying different published criteria. Predictors of non-response included higher BMI (OR1.14; 95% CI1.061.23; p<0.001), admissions at ICU (2.69; 1.305.56; p=0.01), high count of SAE (1.21; 1.031.42; p=0.02) before biologic treatment. High FEV1% (0.96; 0.950.98; p<0.001), a high ACT score (0.93; 0.880.99; p=0.01) before biologic treatment or NSAID-ERD (0.52; 0.290.91; p=0.02) showed strong associations with achieving clinical remission.ConclusionA substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons. (AU)Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Asthma
/
Biological Products
/
Anti-Asthmatic Agents
/
Omalizumab
Limits:
Humans
Language:
En
Journal:
Arch. bronconeumol. (Ed. impr.)
Year:
2024
Document type:
Article